Hyderabad's Best Gastroenterologists Near You | Dr. Kiran
2018/2019 : GS-US- 419-3895 (DIVERSITY1) : Combined Phase 3, Double blind, Randomized, Placebo controlled studies evaluating the Efficacy and Safety of Filgotinib in the induction and maintenance of remission in Moderately to severely active Crohns disease 2018/ 2019: GS - US- 419-3896 (DIVERSITY LTE): A long term extension study to evaluate safety of Filgotinib in subjects with Crohns disease2018/2019: GS-US-418-3898 (SELECTION1): Combined Phase2b/ 3, Double blind, Randomized, Placebo controlled studies evaluating the Efficacy and Safety of Filgotinib in the induction and maintenance of remission in Moderately to severely active Ulcerative colitis
Click to Visit Site